3 results
Approved WMOCompleted
The primary objective of this study is to evaluate efficacy and safety. Secondary objectives: PK, PK-PD.
Approved WMOPending
To establish the preferred treatment of AIN to prevent the development of severe anal neoplasia (persistent AIN III or anal carcinoma) in HIV+ MSM and HIV+ woman.
Approved WMOPending
To establish the safety and tolerablity of multiple doses of hLF1-11 given once daily for 10 days.